source
- Grail’s Galleri blood test sees 33% stock jump as FDA hints at favorable advisory panel outlookShares of Grail rose sharply on Monday after the FDA released documents ahead of an advisory committee meeting, suggesting a positive view of the company’s multi‑cancer blood test, Galleri. The up…
- FDA approves Lilly's new combination therapy for advanced breast cancerThe U.S. Food and Drug Administration has granted approval for a new combination drug regimen developed by Eli Lilly for patients with an advanced form of breast cancer. The therapy pairs two agen…